Revision history of "Substitute for Red Blood" (Q107912)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

10 October 2024

  • curprev 16:0116:01, 10 October 2024DG Regio talk contribs 90,492 bytes −1 Changed label, description and/or aliases in pt
  • curprev 16:0116:01, 10 October 2024DG Regio talk contribs 90,493 bytes −65 Set a claim value: summary (P836): O tema do projeto é a realização de trabalhos de I & D, a fim de desenvolver um substituto seguro para os glóbulos vermelhos, os chamados. «sangue artificial» para uso terapêutico em seres humanos. Atualmente, este tipo de produto não é oferecido no mercado nacional, bem como no mercado europeu e nos EUA. Isto demonstra a elevada capacidade de inovação da solução desenvolvida. Tendo em conta a procura crescente de sangue e dos seus componentes e as...

20 March 2024

15 January 2024

14 June 2023

12 June 2023

24 May 2023

10 March 2023

9 March 2023

2 March 2023

26 January 2023

25 January 2023

20 October 2022

27 July 2022

  • curprev 11:4911:49, 27 July 2022DG Regio talk contribs 83,334 bytes +53,257 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

18 January 2022

15 January 2022

17 December 2021

7 December 2021

1 December 2021

  • curprev 10:2910:29, 1 December 2021DG Regio talk contribs 18,084 bytes +3,053 Created claim: summary (P836): L’objectif du projet est de mener des travaux de R & D afin de mettre au point un substitut sûr aux globules rouges. «sang artificiel», destiné à des usages thérapeutiques chez l’homme. À l’heure actuelle, ce type de produit n’est pas offert sur le marché intérieur, ni sur le marché européen ni aux États-Unis. Cela démontre la forte innovation de la solution en cours de développement. Compte tenu de la demande croissante de sang et de ses compos...
  • curprev 10:2910:29, 1 December 2021DG Regio talk contribs 15,031 bytes +85 Changed label, description and/or aliases in fr: translated_label

29 October 2020

17 October 2020

  • curprev 17:1517:15, 17 October 2020DG Regio talk contribs 15,385 bytes +83 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 17:1517:15, 17 October 2020DG Regio talk contribs 15,302 bytes −79 Changed label, description and/or aliases in 1 language: remove_english_label
  • curprev 17:1517:15, 17 October 2020DG Regio talk contribs 15,381 bytes +2,729 Created claim: summary (P836): The subject of the project is to carry out R & D works, in order to develop a safe substitute for red blood cells, called the so-called. “artificial blood” for therapeutic use in humans. Currently, this type of product is not offered on the domestic market as well as on the European market and in the USA. This demonstrates the high innovativeness of the developed solution. In view of the growing demand for blood and its components and the limita...
  • curprev 17:1517:15, 17 October 2020DG Regio talk contribs 12,652 bytes −2,293 Removed claim: summary (P836): The project involves the development of R & D in order to develop a safe substitute for red blood cells, so called ‘artificial blood’ for therapeutic uses in humans. Currently, this product type is not offered on the domestic market, as well as in the European and US markets. This is evidenced by the highly innovative nature of the solution being developed. In view of the increasing demand for blood and its components and the limitations of na...

24 September 2020

17 July 2020

22 June 2020

10 June 2020

6 June 2020

26 March 2020

9 March 2020

  • curprev 09:5809:58, 9 March 2020DG Regio talk contribs 13,231 bytes +2,293 Created claim: summary (P836): The project involves the development of R & D in order to develop a safe substitute for red blood cells, so called ‘artificial blood’ for therapeutic uses in humans. Currently, this product type is not offered on the domestic market, as well as in the European and US markets. This is evidenced by the highly innovative nature of the solution being developed. In view of the increasing demand for blood and its components and the limitations of nati...

24 February 2020

18 February 2020

31 January 2020

14 January 2020